UK science and innovation VC funding increases to £1.1 billion in 1st-qtr
According to property advisor Knight Frank, venture capital (VC) funding into the UK life sciences sector reached £1.1 billion ($1.3 billion) in the first quarter of 2025, the strongest first quarter since 2021’s post-pandemic peak and around 36% increase versus fourth quarter 2024.
Much of the recent capital investment was concentrated in just two VC deals, with Isomorphic Labs and Verdiva Bio attracting a combined £800 million in funding.
While this highlights renewed investor interest in the UK’s most innovative start-ups and scale-ups, it also underscores the need for more capital to flow across a broader range of companies. Spreading investment more widely will be critical to turbocharging growth, supporting a sustained rebound and ultimately driving a significant uplift in real estate take-up.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze